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was deﬁ  ned by a >4-fold increase in 
inﬂ  uenza-speciﬁ  c hemagglutinin inhi-
bition assay titer between baseline and 
convalescent-phase serum samples 
by using turkey erythrocytes and A/
TN/1560/2009(H1N1), a representa-
tive pandemic inﬂ  uenza virus.
Of the 422 nurses included in the 
analysis, 42 (10.0%) showed serocon-
version to pandemic (H1N1) 2009. Of 
128 nurses who received the trivalent 
inﬂ   uenza vaccine, 9 (7.0%) showed 
seroconversion vs. 33 (11.2%) of 
those that did not (relative risk 0.63, 
95% conﬁ  dence interval 0.31–1.27, p 
= 0.19).
Although the point estimate was 
protective, the conﬁ  dence interval is 
wide and does not exclude an increase 
in risk. Our sample size limits infer-
ences that can be drawn. Heterotypic 
antibodies may have contributed to the 
relatively high rate of seroconversion. 
A rise in antibody titer is considered 
by some as an outcome associated 
with bias, unlike virus identiﬁ  cation.   
Nevertheless, these data suggest a pos-
sible positive effect of seasonal inﬂ  u-
enza vaccine reducing risk of infection 
with pandemic (H1N1) 2009.
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Patients with 
Pandemic (H1N1) 
2009 in Intensive 
Care Units, Israel
To the Editor: We report re-
sults of an active surveillance system 
established by the Tel Aviv District 
Health Ofﬁ  ce in Israel. This surveil-
lance system monitors the daily status 
of patients with laboratory-conﬁ  rmed 
pandemic (H1N1) 2009 virus infec-
tion in each of the district’s intensive 
care units (ICUs), including pediatric 
ICUs.
Follow-up is maintained by daily 
phone conversations with medical 
staff until disease outcome is con-
cluded by discharge, transfer to a 
long-term rehabilitation facility, or 
death. Medical records, as well as 
daily laboratory reports, are collected 
to conﬁ  rm or to rule out pandemic 
(H1N1) 2009 infection.
During July 10–October 10, 
2009, our prospective cohort included 
17 patients with pandemic (H1N1) 
2009 laboratory-conﬁ  rmed  infection 
who were residents of the district; 12 
(70.6%) were male patients. The me-
dian age was 44 years (interquartile 
range 13–72 years). By October 10, 
2009, six patients had been discharged, 
7 had died, 2 had been transferred to 
long-term rehabilitation facilities, and 
2 remained hospitalized.
Twelve (70.6%) patients had an 
underlying medical condition, mainly 
chronic lung disease (6 patients) or 
chronic cardiovascular disease (5 pa-
tients). Two patients were morbidly 
obese (body mass index >35), and 1 
patient was pregnant. Additionally, 3 
patients (17.6%) were infected while 
hospitalized. 
Thirteen patients (76.5%) had 
acute respiratory distress syndrome 
caused by diffuse viral pneumonitis. 
Other notable manifestations were 
acute renal failure (6 patients), sepsis/
septic shock (5 patients), and neuro-
logic complications such as Guillain-
Barré syndrome, encephalitis, and sei-
zures (3 patients). 
Documented nosocomial sepsis, 
often of multiple gram-negative bacte-
ria (9 patients), was the most frequent 
complication during the course of the 
disease. Other frequent characteristics 
were the use of high positive end-ex-
piratory pressure during mechanical 
ventilation (4 patients) and the need 
for tracheostomy (5 patients).
Average time from disease on-
set to hospital admission was 3 days. 
Time from hospital admission to ICU 
admission for those patients who died 
was longer than for those who sur-
vived, with a median of 2 days com-
pared with 0.5 day, respectively, al-
beit not signiﬁ  cant (p = 0.26). Average 
hospitalization was 23.4 days; average 
length of stay in the ICU was 16.7 
days (71.4% of the average hospital-
ization time).
As mentioned previously, 7 pa-
tients (41.2%) died; 5 (71.4%) were 
male, similar to their cohort’s pro-
portion. One signiﬁ  cant difference (p 
= 0.02) was found between the age 
of survivors (mean 26.0 years, 95% 
conﬁ  dence interval 7.6–44.3) and the 
age of nonsurvivors (mean 59.3 years, 
95% conﬁ   dence interval 39.6–79.0). 
The most prominent case–fatality rate 
was for elderly patients, >65 years of 
age (3 of 4 patients) followed by pa-
tients between 20 and 64 years of age 
(4 of 9 patients); these subgroups con-
stituted 23.5% and 52.9% of the co-
hort, respectively.
Estimated incidence rate was 13.8 
patients and 5.7 deaths in ICUs per 
million residents in the Tel Aviv dis-
trict. Again, the elderly subgroup was 
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dominant, with the highest estimated 
rate of illness (23.1 per million resi-
dents) and death rate (17.3 per million 
residents). The denominator of these 
rates was calculated from the popula-
tion data published by the Israeli Cen-
tral Bureau of Statistics for 2007 and 
2008. Upon that basis, the population 
data for the end of the third quarter of 
2009 was estimated. 
During the described surveillance 
period, 5.7% of ICU beds in the dis-
trict were, on average, continuously 
occupied by patients infected with 
pandemic (H1N1) 2009. The occupan-
cy peak was 6.5 of 53.8 standardized 
ICU beds (12.1%) per million resi-
dents during the week ending August 
28, 2009 (Figure).
In conclusion, our analysis of 
patients having the most severe pan-
demic (H1N1) 2009 infection indi-
cates a need for prolonged periods of 
hospitalizations, especially in ICUs, 
for young adults and elderly patients. 
Death or prolonged adverse com-
plications were frequent outcomes. 
We found that the impact of patients 
with pandemic (H1N1) 2009 on the 
ICUs in our district during the sum-
mer wave was surprisingly similar in 
length and intensity to the impact that 
was recently reported in Australia and 
New Zealand during the winter wave 
(1). The maximum number of ICU 
beds occupied per million residents, 
reported for all regions of Australia 
and New Zealand combined, was 7.4 
during the week ending July 27, 2009 
(vs. 6.5 as described above). We also 
found that the mean age of those who 
died was older than that in previous 
reports (2–6).This ﬁ  nding may present 
a need for policymakers to reconsider 
current vaccination priorities (7) while 
facing the winter wave of inﬂ  uenza in 
the Northern Hemisphere. 
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Figure. Number of intensive care unit (ICU) beds occupied by patients with pandemic 
(H1N1) 2009 infection in district ICUs during the described surveillance period, Tel Aviv, 
Israel. During this period, 5.7% of ICU beds, on average, were continuously occupied 
by patients with pandemic (H1N1) 2009 infection. The occupancy peak was 6.5 of 53.8 
standardized ICU beds per million residents (12.1%) during the week ending August 28, 
2009. Data are per million residents.